Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes.

A highly selective and potent PTP-MEG2 inhibitor with therapeutic potential for type 2 diabetes. J Am Chem Soc. 2012 Oct 31; 134(43):18116-24.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.